MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.
Company profile
Ticker
MPSYF
Exchange
Website
CEO
Jean-Paul Kress
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
MPSYF stock data
Latest filings (excl ownership)
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Oct 24
POSASR
Automatic shelf registration (post-effective amendment)
4 Oct 24
6-K
Half-Year Report JANUARY – JUNE 2024
29 Aug 24
6-K
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
27 Aug 24
Transcripts
Latest ownership filings
SC 13D/A
NOVARTIS AG
15 Aug 24
SC 13D/A
NOVARTIS AG
21 Jun 24
SC 13D/A
NOVARTIS AG
17 Jun 24
SC 13D/A
NOVARTIS AG
10 Jun 24
SC 13G/A
GOLDMAN SACHS GROUP INC
10 Jun 24
SC 13D/A
NOVARTIS AG
28 May 24
SC 13D
NOVARTIS AG
18 Apr 24
SC 13G
GOLDMAN SACHS GROUP INC
11 Mar 24
SC 13G/A
Kynam Capital Management, LP
8 Mar 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
16 Feb 24
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2024
95.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 7 |
Closed positions | 32 |
Increased positions | 8 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 32.36 bn |
Total shares | 36.08 mm |
Total puts | 687.70 k |
Total calls | 79.80 k |
Total put/call ratio | 8.6 |
Largest owners | Shares | Value |
---|---|---|
NVS Novartis | 34.34 mm | $624.95 mm |
BLK BlackRock | 1.02 mm | $18.51 bn |
Segantii Capital Management | 463.47 k | $8.41 bn |
Hennion & Walsh Asset Management | 124.55 k | $2.27 bn |
Henry James International Management | 88.51 k | $1.61 bn |
Engineers Gate Manager | 13.42 k | $244.17 mm |
Advisors Preferred | 6.50 k | $118.09 mm |
Quadrant Capital | 5.93 k | $107.89 mm |
Rhumbline Advisers | 5.19 k | $94.40 mm |
BAC Bank of America | 3.40 k | $61.90 mm |
Press releases
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
27 Aug 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
17 Jul 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI, MGOL on Behalf of Shareholders
15 Jul 24
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR
15 Jul 24
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
12 Jul 24